Ex-ImClone CEO Lynch joins Third Rock; TetraLogic raises venture take to $43M; regulators want new Ph3 for Huntington's drug;

@FierceBiotech:  Sanofi's Zerhouni drops biotech model in favor of "open innovation." Story | Follow @FierceBiotech

@JohnCFierce: Panel at BIO June 29 includes execs from AstraZeneca, Acorda, HGS and Sanofi. Follow @JohnCFierce

> Former ImClone CEO Dan Lynch has joined up with Third Rock as an entrepreneur-in-residence. Third Rock, an active venture player, has spawned a string of biotech start-ups in recent years. And it often turns to its entrepreneurs to fill top slots. Release

> TetraLogic Pharmaceuticals has closed a $6 million investment with new investor Nextech Invest. Combined with the $37 million Series C closed during 2010, TetraLogic has raised $43 million in the past year. Release

> Denmark's Neurosearch says that it will need to mount a new Phase III study if it expects to win over regulators in Europe for its Huntington's drug Huntexil. Story

> The once-promising UK biotech Antisoma is now down to 0 full time employees, reports Pharma Times. The board says it's studying its "options." Story

> Ampio Pharmaceuticals is touting late-stage results for its new drug for premature ejaculation. Ampio says it is now in a position to file for approval of Zertane in Europe. Report

Pharma News

@FiercePharma: Facebook: No more 'no comment' for pharma. News | Follow @FiercePharma

> Shire may look to bulk up with $2B Cubist deal. Report

> NICE approves MabThera for lymphoma maintenance. Story

> AZ to co-promote Amgen bone drug in Japan. News

> Lilly launches new venture to market Xigris. Item

> Prompted by Tamiflu probe, Canada mulls conflicts disclosure. Piece

Biotech Research News

> Scientists find better mouse model for major depressive disorder. News 

> Scientists use stem cells to cook up a batch of astrocytes, the brain's workhorses. Item 

> Brain has protective proteins that make it stronger after attack. Article 

> Heart failure progression is in the PINK1 gene. Story

>  WHO decides not to decide on remaining smallpox stockpiles. Item 

Manufacturing News

> QbD process steps studied in regulatory pilot. Report

> Thieves target generics in Pfizer trailer heist. News

> Issa wants FDA speed on J&J rehab. Item

> FTC asked to consider drug supply in pharma rulings. Story

> Show product flow in plant design plans. Report

And Finally...Mummies found along the Nile point to age-old irrigation techniques as a prime culprit behind the plague of schistosomiasis which infects an estimated 200 million people. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."